Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityAKCA / Akcea Therapeutics Inc. (00972L107)
President & CEOSoteropoulos Paula
Institutional Owners60
Institutional Shares22,799,043 - 26.60%
Common Shares Outstanding85,718,372 shares (as of 2018-06-30)
Institutional Value$ 556,674,000 USD

Institutional Stock Ownership and Shareholders()

AKCA / Akcea Therapeutics Inc. Institutional Ownership

Akcea Therapeutics Inc. (NASDAQ:AKCA) has 60 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 22,799,043 shares. Largest shareholders include FMR LLC / Fidelity, Wellington Management Group LLP, Bb Biotech Ag, BlackRock Inc., Vanguard Group Inc, Bellevue Group AG, State Street Corp, Geode Capital Management, Llc, Altrinsic Global Advisors Llc, and Northern Trust Corp.
Akcea Therapeutics Inc. (NASDAQ:AKCA) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-11 13F-HR Delpha Capital Management, Llc 1,521 0 -100.00 26 0 -100.00
2018-08-14 13F-HR/A CITADEL ADVISORS LLC Call 20,600 36,400 76.70 528 863 63.45
2018-08-14 13F-HR/A CITADEL ADVISORS LLC Put 9,200 218
2018-08-06 13F-HR Sonora Investment Management, LLC 50 50 0.00 1,281 1 -99.92
2018-08-08 13F-HR AMERICAN INTERNATIONAL GROUP INC 9,588 8,307 -13.36 246 197 -19.92
2018-08-14 13F-HR JP Morgan Chase & Co 4,735 4,318 -8.81 121 102 -15.70
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 6,878 12,368 79.82 176 293 66.48
2018-08-13 13F-HR ALLIANCEBERNSTEIN L.P. 25,600 36,400 42.19 656 863 31.55
2018-08-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 14,800 14,200 -4.05 379 337 -11.08
2018-08-13 13F-HR GROUP ONE TRADING, L.P. Put 3,600 10,500 191.67 92 249 170.65
2018-08-14 13F-HR MORGAN STANLEY 36,070 127,289 252.89 924 3,018 226.62
2018-08-13 13F-HR Advisor Group, Inc. 100 2
2018-08-14 13F-HR Tower Research Capital LLC (TRC) 1,595 3,477 117.99 41 82 100.00
2018-08-14 13F-HR QS Investors, LLC 50 54 8.00 1 1 0.00
2018-08-13 13F-HR ProShare Advisors LLC 32,725 37,651 15.05 838 893 6.56
2018-08-14 13F-HR TEACHERS ADVISORS INC 27,855 26,257 -5.74 713 623 -12.62
2018-08-06 13F-HR STRS OHIO 4,300 14,700 241.86 110 348 216.36
2018-08-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 13,015 11,687 -10.20 333 277 -16.82
2018-08-10 13F-HR FMR LLC / Fidelity 10,008,016 12,455,383 24.45 256,306 295,317 15.22
2018-08-10 13F-HR VIRTUS ETF ADVISERS LLC 39,351 33,315 -15.34 1,008 790 -21.63
2018-08-14 13F-HR VANGUARD GROUP INC 1,123,758 1,159,797 3.21 28,779 27,499 -4.45
2018-08-07 13F-HR Bellevue Group AG 48,799 379,301 677.27 1,250 8,993 619.44
2018-08-10 13F-HR Cutler Group LP Call 3,000 6
2018-08-14 13F-HR ROYAL BANK OF CANADA 59 64 8.47 1 2 100.00
2018-08-14 13F-HR Paloma Partners Management Co 9,100 216
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 20,700 32,200 55.56 530 763 43.96
2018-08-10 13F-HR CITIGROUP INC 125 0 -100.00 3 0 -100.00
2018-07-30 13F-HR/A Virtu Financial LLC 12,571 8,722 -30.62 322 207 -35.71
2018-08-09 13F-HR BB BIOTECH AG 2,389,571 2,484,071 3.95 61,197 58,897 -3.76
2018-07-30 13F-HR Daiwa Securities Group Inc. 368 368 0.00 9 9 0.00
2018-08-14 13F-HR BARCLAYS PLC 11,312 14,365 26.99 290 340 17.24
2018-07-24 13F-HR ACADIAN ASSET MANAGEMENT LLC 149 0 -100.00 4 0 -100.00
2018-08-14 13F-HR Wellington Management Group LLP 3,384,101 2,604,557 -23.04 86,667 61,754 -28.75
2018-08-09 13F-HR Swiss National Bank 28,300 28,300 0.00 725 671 -7.45
2018-07-25 13F-HR BNP PARIBAS ARBITRAGE, SA 3,433 685 -80.05 87,919 16,241 -81.53
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 207,139 203,131 -1.93 5,304 4,816 -9.20
2018-08-03 13F-HR SEI INVESTMENTS CO 8 8 0.00 0 0
2018-08-14 13F-HR UBS Group AG 200 219 9.50 5 5 0.00
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 90 2
2018-08-10 13F-HR Cutler Group LP 127 400 214.96 3 9 200.00
2018-08-14 13F-HR FIFTH THIRD BANCORP 150 4
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 8,983 213
2018-02-09 13F-HR RidgeWorth Capital Management LLC 18,071 314
2018-08-06 13F-HR RHUMBLINE ADVISERS 13,064 12,246 -6.26 335 290 -13.43
2018-08-08 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 76,142 71,060 -6.67 1,950 1,685 -13.59
2018-08-14 13F-HR NORTHERN TRUST CORP 170,924 181,110 5.96 4,378 4,294 -1.92
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 23,865 34,052 42.69 611 807 32.08
2018-08-15 13F-HR Metlife Investment Advisors, Llc 7,356 0 -100.00 188 0 -100.00
2018-08-14 13F-HR GOLDMAN SACHS GROUP INC 43,777 64,103 46.43 1,121 1,520 35.59
2018-08-02 13F-HR/A ALPS ADVISORS INC 123,368 2,925
2018-08-14 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 23,179 19,516 -15.80 594 463 -22.05
2018-08-14 13F-HR CREDIT SUISSE AG/ 26,365 14,223 -46.05 676 337 -50.15
2018-07-27 13F-HR PIEDMONT INVESTMENT ADVISORS LLC 221 5
2018-08-06 13F-HR Zurcher Kantonalbank (Zurich Cantonalbank) 4,300 4,300 0.00 110 102 -7.27
2018-08-10 13F-HR Legal & General Group Plc 2,705 1,899 -29.80 69 45 -34.78
2018-05-15 13F-HR Iguana Healthcare Management, LLC 100,000 0 -100.00 1,736 0 -100.00
2018-08-09 13F-HR BlackRock Inc. 1,780,363 1,901,547 6.81 45,594 45,087 -1.11
2018-08-15 13F-HR METROPOLITAN LIFE INSURANCE CO/NY 5,008 0 -100.00 128,255 0 -100.00
2018-08-14 13F-HR STATE STREET CORP 260,309 260,009 -0.12 6,664 6,167 -7.46
2018-05-11 13F-HR CITIGROUP INC 129 125 -3.10 2 3 50.00
2018-08-13 13F-HR GROUP ONE TRADING, L.P. Call 17,900 11,800 -34.08 458 280 -38.86
2018-08-13 13F-HR Quantbot Technologies LP 4,089 5,751 40.65 104 136 30.77
2018-08-10 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 2,062 2,062 0.00 53 49 -7.55
2018-08-14 13F-HR DEUTSCHE BANK AG\ 16,289 33,829 107.68 416 801 92.55
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 25,300 28,000 10.67 648 664 2.47
2018-08-14 13F-HR BOOTHBAY FUND MANAGEMENT, LLC 11,400 270
2018-08-10 13F-HR Cutler Group LP Put 800 3,000 275.00 1 7 600.00
2018-08-13 13F-HR Ameritas Investment Partners, Inc. 1,275 1,275 0.00 33 30 -9.09
2018-08-06 13F-HR Bank of New York Mellon Corp 64,984 56,558 -12.97 1,665 1,341 -19.46
2018-08-13 13F-HR ALTRINSIC GLOBAL ADVISORS LLC 187,800 197,800 5.32 4,810 4,690 -2.49
2018-08-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 48,808 32,653 -33.10 1,250 774 -38.08
2018-08-14 13F-HR Parallax Volatility Advisers, L.P. 326 0 -100.00 8 0 -100.00
2018-08-15 13F-HR JANE STREET GROUP, LLC 20,456 0 -100.00 524 0 -100.00
2018-08-14 13F-HR EVENTIDE ASSET MANAGEMENT, LLC 175,000 0 -100.00 4,482 0 -100.00
2018-08-14 13F-HR MILLENNIUM MANAGEMENT LLC 12,104 63,998 428.73 310 1,517 389.35
2018-08-14 13F-HR PERCEPTIVE ADVISORS LLC 97,144 0 -100.00 2,488 0 -100.00
2018-08-14 13F-HR Cubist Systematic Strategies, LLC 7,843 0 -100.00 201 0 -100.00

Related Articles

RNVA: Rennova Health Analysis and Research Report

2018-08-18 - Asif

Business overview Rennova Health, Inc. (together with its subsidiaries, “Rennova”, “we” or the “Company”) is a provider of an expanding group of health care services for healthcare providers, patients and individuals. Beginning in 2018, the Company intends to focus on and operate two synergistic divisions: 1) Clinical diagnostics through its clinical laboratories; and 2) Hospital operations through its Big South Fork Medical Center, which opened on August 8, 2017, and a hospital in Jamestown Tennessee, including a doctor’s practice, the assets of which the company expect to acquire in the second quarter of 2018, pursuant to the terms of a definitive asset purchase agreement that the company entered into on January 31, 2018, as more fully discussed below. The company believe that its approach will produce a more sustainable business model and the capture of multiple revenue streams from medical providers, patients and hospital services. Management determined that because Big So...

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

Related News Stories

The Battle For Best-In-Class In ATTR Has Begun

2018-08-16 seekingalpha
There will be significant competition for the limited number of ATTR patients - approximately 10k with ATTR-PN, 40k with ATTR-CM, and 200k with ATTRwt. (12-0)

Alnylam Receives FDA Approval for First-Ever RNA Interference Therapeutic

2018-08-13 biospace
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Onpattro (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It is the first and only RNA interference (RNAi) therapeutic to ever be approved.

FDA Approves Alnylam's Onpattro for Polyneuropathy of hATTR Amyloidosis

2018-08-11 genengnews
The FDA today granted Alnylam Pharmaceuticals approval for a first-in-class small interfering ribonucleic acid (siRNA) treatment—the first therapy indicated for polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adults. (0-2)

Akcea Therapeutics' (AKCA) CEO Paula Soteropoulos on Q2 2018 Results - Earnings Call Transcript

2018-08-07 seekingalpha
Good afternoon, and welcome to the Akcea Therapeutics Second Quarter 2018 Conference Call. As a reminder, this call is being recorded. Leading the call today is Paula Soteropoulos, Akcea’s Chief Executive Officer. Ms. Soteropoulos, please begin.

Your Daily Pharma Scoop: Epizyme Down, MiMedx Proceeds, Summit Beats

2018-08-05 seekingalpha
Epizyme down 8% premarket on termination of tazemetostat in DLBCL & delay in NDA filing for ES (42-2)

CUSIP: 00972L107